Study

Open-Label Uridine for Treatment of Depressed Adolescents with Bipolar Disorder – Cost Effective Supplements

Open-Label Uridine for Treatment of Depressed Adolescents with Bipolar Disorder

Quick navigation


http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3080753/


Conclusion of this study

In this pilot case series, uridine was efficacious and well tolerated by study participants. Rapid onset of action may be a distinguishing feature of uridine. Open-label studies are an initial step in testing a novel intervention, and these findings should be considered preliminary. Uridine should not enter clinical practice as a primary treatment for depressed adolescents with bipolar disorder until randomized placebo-controlled trials have been performed to confirm its efficacy.


Supplements analyzed in this study

Uridine

Health conditions analyzed in this study

Bipolar Disorder


Slightly Positive
Uridine

Depression


Slightly Positive
Uridine


Functions related to this study

Emotional health


Slightly Positive
Uridine

Mental health


Slightly Positive
Uridine


Body systems related to this study


Nervous System
Scroll to top